InvestorsHub Logo
Followers 2
Posts 60
Boards Moderated 0
Alias Born 12/19/2012

Re: None

Friday, 09/13/2019 11:08:19 AM

Friday, September 13, 2019 11:08:19 AM

Post# of 403047
As Alfasigma USA moves forward with Zelnorm, Downey said the company is expanding its pipeline in order to grow its presence in the pharmaceutical space. In July, the company licensed Brilacidin from Innovation Pharmaceuticals for more than $24 million. Alfasigma will develop Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. The company is also working with Theravance Biopharma to develop velusetrag for gastroparesis. Downey said he anticipates 2023 or 2024 for the first significant news out of those assets. The company is also working with Salix Pharmaceuticals to develop a reformulation of Xifaxin as a treatment for Crohn’s disease.

https://www.biospace.com/article/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News